Category: 3. Business

  • A Look At The Intrinsic Value Of iomart Group plc (LON:IOM)

    A Look At The Intrinsic Value Of iomart Group plc (LON:IOM)

    • Using the 2 Stage Free Cash Flow to Equity, iomart Group fair value estimate is UK£0.28

    • Current share price of UK£0.26 suggests iomart Group is potentially trading close to its fair value

    • Analyst price target for IOM is UK£0.53, which is 87% above our fair value estimate

    Today we will run through one way of estimating the intrinsic value of iomart Group plc (LON:IOM) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. There’s really not all that much to it, even though it might appear quite complex.

    Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

    AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

    We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second ‘steady growth’ period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren’t available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

    A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today’s dollars:

    2026

    2027

    2028

    2029

    2030

    2031

    2032

    2033

    2034

    2035

    Levered FCF (£, Millions)

    UK£200.0k

    UK£3.30m

    UK£6.40m

    UK£5.20m

    UK£4.56m

    UK£4.21m

    UK£4.02m

    UK£3.93m

    UK£3.90m

    UK£3.92m

    Growth Rate Estimate Source

    Analyst x2

    Analyst x2

    Analyst x1

    Est @ -18.80%

    Est @ -12.26%

    Est @ -7.69%

    Est @ -4.48%

    Est @ -2.24%

    Est @ -0.67%

    Est @ 0.43%

    Present Value (£, Millions) Discounted @ 13%

    UK£0.2

    UK£2.6

    UK£4.4

    UK£3.2

    UK£2.5

    UK£2.0

    UK£1.7

    UK£1.5

    UK£1.3

    UK£1.1

    (“Est” = FCF growth rate estimated by Simply Wall St)
    Present Value of 10-year Cash Flow (PVCF) = UK£20m

    Continue Reading

  • Assessing Constellation Brands After Expansion Into New Beverage Categories and Recent Price Recovery

    Assessing Constellation Brands After Expansion Into New Beverage Categories and Recent Price Recovery

    • Wondering if Constellation Brands is a hidden gem or if the market’s already caught on to its true value? You’re not alone. This deep dive is for you.

    • The stock saw a 3.5% bump over the past week but is still down 39.9% year-to-date. This shows just how much sentiment has shifted lately.

    • Recently, Constellation Brands has been in the news for its expansion into new beverage categories and its strategic acquisition activity. These moves are helping to reshape its portfolio, which could explain some of the volatility as investors reassess future growth prospects and risks.

    • According to our valuation checks, the company scores 4 out of 6 for being undervalued. This puts it ahead of many peers, but not quite in the clear just yet. Let’s break down how we arrive at this score and why, later in the article, you’ll see there is an even more insightful way to look at valuation that most investors miss.

    Find out why Constellation Brands’s -42.8% return over the last year is lagging behind its peers.

    A Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by forecasting its future cash flows and then discounting those back to their value today. In Constellation Brands’ case, analysts project free cash flow (FCF) for the next few years, and further projections are created using reasonable expectations for the company’s industry and market position.

    Currently, Constellation Brands is generating free cash flow of about $1.63 billion. Analyst estimates, supplemented by extrapolations, suggest this could rise to approximately $2.52 billion by 2030. The DCF model used here is a two-stage approach. This means it considers both near-term growth (driven by analyst forecasts up to 2027) and longer-term potential (extrapolated beyond that date).

    Based on these projections and discounted back to today’s dollars, the estimated intrinsic value of Constellation Brands comes out to $332.88 per share. With the stock trading at nearly a 59.8% discount to this fair value, the evidence points strongly toward the stock being undervalued at current prices.

    Result: UNDERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests Constellation Brands is undervalued by 59.8%. Track this in your watchlist or portfolio, or discover 927 more undervalued stocks based on cash flows.

    STZ Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Constellation Brands.

    The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics for established, profitable companies like Constellation Brands. It helps investors understand how much they are paying for each dollar of a company’s earnings, making it especially practical for businesses with consistent profit generation.

    Continue Reading

  • Assessing NRG Energy’s Value After a 71.6% Price Surge in 2025

    Assessing NRG Energy’s Value After a 71.6% Price Surge in 2025

    • If you have ever wondered whether NRG Energy is undervalued or overpriced right now, you are not alone. Many investors are asking the same question about this high-performing stock.

    • Despite a slight dip of 3.6% over the last week and 6.6% over the past month, NRG Energy has posted a 71.6% gain year-to-date and a 69% return over the past year.

    • NRG’s stock price has recently responded to several pivotal developments, including changes in energy market dynamics, regulatory updates, and the company’s ongoing push into decarbonization and innovative energy solutions. These headlines have influenced investor sentiment and highlight the shifting landscape in which NRG is operating.

    • On the valuation front, NRG scores a 3 out of 6 in our value assessment here, indicating some undervalued characteristics but also suggesting room for further investigation. Next, we will break down how different valuation methods apply to NRG Energy, and at the end of the article, reveal an approach that may provide the most comprehensive view yet.

    NRG Energy delivered 69.0% returns over the last year. See how this stacks up to the rest of the Electric Utilities industry.

    The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future cash flows and discounting them back to today’s dollars. This method is widely used because it focuses on the actual cash a business is expected to generate, offering a fundamental view of value.

    For NRG Energy, the latest reported Free Cash Flow (FCF) stands at $2.03 Billion. Analyst estimates suggest steady growth, with projections reaching $3.19 Billion by 2026 and $4.68 Billion by 2029. Beyond that, Simply Wall St extrapolates further increases, projecting FCF of $5.38 Billion by 2035. All cash flows are in US dollars.

    Based on these projections, the DCF model calculates NRG Energy’s intrinsic value at $567.34 per share. When compared to the current market price, this implies the stock is trading at a 71.9% discount to its estimated fair value. This significant discount suggests the market may be undervaluing the company’s potential future cash flows.

    Result: UNDERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests NRG Energy is undervalued by 71.9%. Track this in your watchlist or portfolio, or discover 927 more undervalued stocks based on cash flows.

    NRG Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for NRG Energy.

    The Price-to-Earnings (PE) ratio is widely regarded as an effective valuation metric for profitable companies like NRG Energy because it directly links a company’s market price to its earnings performance. Investors gravitate towards the PE ratio as it helps gauge whether a stock is trading at a reasonable multiple of its earnings, making it easier to compare companies in the same sector.

    Continue Reading

  • Nu Holdings (NYSE:NU) Valuation Spotlight After Surging Growth, Expanding Client Base, and Q3 Earnings Upside

    Nu Holdings (NYSE:NU) Valuation Spotlight After Surging Growth, Expanding Client Base, and Q3 Earnings Upside

    Nu Holdings (NYSE:NU) has delivered a strong third quarter, reporting sharp increases in both net income and earnings per share. The company’s customer base now sits at 127 million, reflecting steady momentum.

    See our latest analysis for Nu Holdings.

    Nu Holdings’ momentum is hard to ignore. Following its third quarter surprise and continued expansion in Latin America, the share price has climbed nearly 50% year-to-date. Long-term investors have been rewarded as well, with a strong 3-year total shareholder return of over 250%, underlining the stock’s remarkable growth trajectory and increasing investor optimism.

    If Nu’s growth story has you wondering where to look next, consider expanding your search and discover fast growing stocks with high insider ownership

    But with shares already up nearly 50% this year and analyst targets just modestly above current levels, the key question remains: Is Nu Holdings offering a true buying opportunity, or is the market already pricing in future growth?

    Nu Holdings’ most closely watched narrative values the stock at $17.98 per share, comfortably above the last close at $15.89. This perspective suggests consensus expectations are factoring in more robust future growth than the current market price reflects.

    The ongoing transition from cash to digital payments and online banking in historically underserved markets continues to accelerate Nu’s transaction volumes and increases opportunities for cross-sell and ecosystem stickiness. This supports robust net margin expansion as digital penetration deepens.

    Read the complete narrative.

    Want to see what ambitious growth forecasts are driving this estimate? The narrative points to rapid expansion, surging profit, and a bold margin outlook. Which numbers turn this outlook into valuation tailwind? Dive deeper to discover what separates this prediction from the crowd.

    Result: Fair Value of $17.98 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, fierce competition and rising credit risks could threaten Nu’s growth momentum. This underscores why continued vigilance remains essential for shareholders.

    Find out about the key risks to this Nu Holdings narrative.

    Looking through the lens of earnings multiples shows a different story. Nu Holdings trades at 30.4 times earnings, which is much higher than the US Banks industry average of 11.2x and its peer average of 11.6x. Even compared to the fair ratio of 20.1x, the premium is significant. This points to valuation risk if growth expectations do not hold up. Are investors paying too much for the Nu story?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:NU PE Ratio as at Nov 2025

    Your perspective might differ, and if you’d rather explore the numbers independently, you can quickly craft your own Nu Holdings outlook in just a few minutes with Do it your way.

    A great starting point for your Nu Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Smart investors always have their eye open for the next winning opportunity. Don’t limit yourself to just one story when a world of potential is a click away.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include NU.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Assessing Panasonic (TSE:6752) Valuation After Recent Share Price Cool-Down and Strong Long-Term Returns

    Assessing Panasonic (TSE:6752) Valuation After Recent Share Price Cool-Down and Strong Long-Term Returns

    Panasonic Holdings (TSE:6752) has captured attention as investors digest recent numbers and look at what the stock’s performance tells us about the company’s direction. The discussion focuses on its underlying fundamentals and how shares have moved over the past year.

    See our latest analysis for Panasonic Holdings.

    Panasonic Holdings’ share price has cooled off a bit over the past month, dipping 4.4%, but that comes after a strong run with a 12.5% gain in the previous quarter. All told, the company’s one-year total shareholder return sits at a solid 15%. The three- and five-year figures, 46% and 75% respectively, suggest that long-term momentum remains firmly intact, reflecting optimism about its growth prospects.

    If you’re curious about what else is building momentum in the sector, now’s a great time to explore the auto manufacturers landscape with See the full list for free.

    But with shares trading at a meaningful discount to analyst targets and robust earnings growth behind it, the key question is whether Panasonic Holdings is undervalued right now or if the market is already factoring in future gains.

    Compared to Panasonic Holdings’ last close price, the most followed narrative assigns a much higher fair value, suggesting the market may be discounting future growth potential. This framework brings together analyst price targets, earnings power, and margin forecasts to set its target.

    Demand for industrial energy storage systems is accelerating beyond initial expectations due to large-scale data center investment driven by generative AI adoption. This is likely to support revenue growth and improve recurring earnings quality in the Energy segment. Despite a near-term EV slowdown in North America from policy headwinds (IRA tax credit termination, tariffs), Panasonic’s locally produced, IRA-compliant battery cells and new high-capacity cell technology are sustaining strong customer demand. This positions the company for volume growth and higher net margins as electrification resumes its long-term trend.

    Read the complete narrative.

    What is behind this bullish price view? The narrative is built on aggressive projections for profit expansion and margin improvement, along with critical long-term bets on new battery technologies. Want to discover exactly how analysts justify this higher valuation and which future milestones could make or break it?

    Result: Fair Value of ¥2,126.67 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, risks such as a slowdown in EV demand or increased tariffs could quickly shift Panasonic Holdings’ outlook away from the current bullish narrative.

    Find out about the key risks to this Panasonic Holdings narrative.

    If this perspective doesn’t quite fit your view, or if you enjoy digging into the numbers yourself, it’s easy to craft your own take in just a few minutes. Do it your way

    A great starting point for your Panasonic Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Missing out on these fresh stock ideas could cost you the opportunity to catch tomorrow’s leaders early. Supercharge your research with these handpicked investment angles below.

    • Tap into long-term income by scanning these 16 dividend stocks with yields > 3% offering impressive yields above 3% and a solid track record of shareholder rewards.

    • Ride the AI momentum by reviewing these 26 AI penny stocks building intelligent solutions for tomorrow’s world and securing footholds in high-growth sectors.

    • Benefit from sector innovation and resilience with these 30 healthcare AI stocks tackling the toughest challenges in medical technology and healthcare advancement.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include 6752.T.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Iannuzzi JP, King JA, Leong JH, Quan J, Windsor JW, Tanyingoh D, et al. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis. Gastroenterology. 2022;162(1):122–34.

    Google Scholar 

  • Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: a review. JAMA. 2021;325(4):382–90.

    Google Scholar 

  • Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, et al. Acute pancreatitis: Diagnosis and treatment. Drugs. 2022;82(12):1251–76.

    Google Scholar 

  • Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet. 2020;396(10252):726–34.

    Google Scholar 

  • Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019;16(8):479–96.

    Google Scholar 

  • IAP/APA evidence-based guidelines for the management of acute pancreatitis, Pancreatology official journal of the International Association of Pancreatology (IAP) et al. 2013;13:e1 15.

  • Hackert T, Werner J. Antioxidant therapy in acute pancreatitis: experimental and clinical evidence. Antioxid Redox Signal. 2011;15(10):2767–77.

    Google Scholar 

  • Liu L, Zhang Y, Li X, Deng J. Microenvironment of pancreatic inflammation: Calling for nanotechnology for diagnosis and treatment. J Nanobiotechnol. 2023;21(1):443.

    Google Scholar 

  • Sah RP, Garg P, Saluja AK. Pathogenic mechanisms of acute pancreatitis. Curr Opin Gastroenterol. 2012;28(5):507–15.

    Google Scholar 

  • Jakkampudi A, Jangala R, Reddy BR, Mitnala S, Reddy DN, Talukdar R, et al. NF-κb in acute pancreatitis: Mechanisms and therapeutic potential. Pancreatology. 2016;16(4):477–88.

    Google Scholar 

  • Vasudevan SO, Behl B, Rathinam VA. Pyroptosis-induced inflammation and tissue damage. Semin Immunol. 2023;69:101781.

    Google Scholar 

  • Du G, Healy LB, David L, Walker C, El-Baba TJ, Lutomski CA, et al. ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D. Nature. 2024;630(8016):437–46.

    Google Scholar 

  • Ren F, Xu J, Zhang J, Xu X, Huang L, Sun W, et al. PM(2.5) induced lung injury through upregulating ROS-dependent NLRP3 inflammasome-mediated pyroptosis. Immunobiology. 2022;227(3):152207.

    Google Scholar 

  • Zhang Y, Fang C, Zhang W, Zhang K. Emerging pyroptosis-engineered nanobiotechnologies regulate cancers and inflammatory diseases: A double-edged sword. Matter. 2022;5(11):3740–74.

    Google Scholar 

  • Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245–54.

    Google Scholar 

  • Zhou J, Fang C, Rong C, Luo T, Liu J, Zhang K. Reactive oxygen species-sensitive materials: A promising strategy for regulating inflammation and favoring tissue regeneration. Smart Mater Med. 2023;4:427–46.

    Google Scholar 

  • Zhang R, Yan X, Fan K. Nanozymes inspired by natural enzymes. Acc Mater Res. 2021;2(7):534–47.

    Google Scholar 

  • Gao L, Wei H, Dong S, Yan X. Nanozymes. Adv Mater. 2024;36(10):e2305249.

    Google Scholar 

  • Liang M, Yan X. Nanozymes: from new concepts, mechanisms, and standards to applications. Acc Chem Res. 2019;52(8):2190–200.

    Google Scholar 

  • Hai X, Xi S, Mitchell S, Harrath K, Xu H, Akl DF, et al. Scalable two-step annealing method for preparing ultra-high-density single-atom catalyst libraries. Nat Nanotechnol. 2022;17(2):174–81.

    Google Scholar 

  • Chen Y, Wang P, Hao H, Hong J, Li H, Ji S, et al. Thermal atomization of platinum nanoparticles into single atoms: An effective strategy for engineering high-performance nanozymes. J Am Chem Soc. 2021;143(44):18643–51.

    Google Scholar 

  • Hua S, Dong X, Peng Q, Zhang K, Zhang X, Yang J. Single-atom nanozymes shines diagnostics of gastrointestinal diseases. J Nanobiotechnol. 2024;22(1):286.

    Google Scholar 

  • Zhang R, Yan X, Gao L, Fan K. Nanozymes expanding the boundaries of biocatalysis. Nat Commun. 2025;16(1):6817.

    Google Scholar 

  • Li Q, Zeng M, Pu XY, Tang Q, Yang Q, Zhang LK. Melittin-Loaded Multifunctional Nanozyme for Ulcerative Colitis Treatment via Enzyme-Immunotherapy and Ferroptosis Inhibition, Advanced functional materials. 2025.

  • Cao F, Jin L, Gao Y, Ding Y, Wen H, Qian Z, et al. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis. Nat Nanotechnol. 2023;18(6):617–27.

    Google Scholar 

  • Chen J, Zhao Y, Ruan R, Feng X, Niu Z, Pan L, et al. Bone morphogenetic protein-2-derived peptide-conjugated nanozyme-integrated photoenhanced hybrid hydrogel for cascade-regulated bone regeneration. ACS Nano. 2025;19(15):14707–26.

    Google Scholar 

  • Li D, Ai Z, Tian Y, Wang Y, Zhang C. Bioactive prosthetic interface constructed with cascading multi-nanozyme hydrogel to induce M2 macrophage polarization and heal diabetic bone defects. Biomaterials. 2025;325:123624.

    Google Scholar 

  • Li H, Wei S, Ling Q, Wang R, Liu T, Yu H, et al. Nanozyme-reinforced hydrogel spray as a reactive oxygen species-driven oxygenator to accelerate diabetic wound healing. Adv mater (Deerfield Beach, Fla). 2025;37(34):e2504829.

    Google Scholar 

  • Xuan Q, Cai J, Gao Y, Qiao X, Jin T, Peydayesh M, et al. Amyloid-templated ceria nanozyme reinforced microneedle for diabetic wound treatments. Adv mater (Deerfield Beach, Fla). 2025;37(15):e2417774.

    Google Scholar 

  • Shan Y, Zhong J, Sun Q, Gao W, Zhang C, Chen H, et al. Dual nanozymes-loaded core-shell microneedle patches with antibacterial and NETs-degradation bifunctional properties for periodontitis treatment. Bioact Mater. 2025;53:161–77.

    Google Scholar 

  • Wang D, Jin H, Shen Y, Wang D, He J, Qu J, et al. NIR-II-activated iridium single-atom nanozymes for synergistic antibacterial therapy and tissue regeneration in MRSA-infected wounds and acute lung injury. Bioact Mater. 2025;51:543–58.

    Google Scholar 

  • Lee H, Krishnan M, Kim M, Yoon YK, Kim Y. Rhamnetin, a natural flavonoid, ameliorates organ damage in a mouse model of carbapenem-resistant acinetobacter baumannii-induced sepsis. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232112895.

    Google Scholar 

  • Novo Belchor M, Hessel Gaeta H, FabriBittencourt Rodrigues C, Ramos C, da Cruz Costa D, de Oliveira Toyama LF, et al. Evaluation of Rhamnetin as an inhibitor of the pharmacological effect of secretory phospholipase A2. Mol (Basel, Switz). 2017;22(9):1420–3049.

    Google Scholar 

  • Park ES, Kang JC, Jang YC, Park JS, Jang SY, Kim DE, et al. Cardioprotective effects of rhamnetin in H9c2 cardiomyoblast cells under H₂O₂-induced apoptosis. J Ethnopharmacol. 2014;153(3):552–60.

    Google Scholar 

  • Bull SD, Davidson MG, van den Elsen JM, Fossey JS, Jenkins AT, Jiang YB, et al. Exploiting the reversible covalent bonding of boronic acids: Recognition, sensing, and assembly. Acc Chem Res. 2013;46(2):312–26.

    Google Scholar 

  • Geng W, Jiang N, Qing GY, Liu X, Wang L, Busscher HJ, et al. Click reaction for reversible encapsulation of single yeast cells. ACS Nano. 2019;13(12):14459–67.

    Google Scholar 

  • Zhang K, Cheng Y, Ren W, Sun L, Liu C, Wang D, et al. Coordination-responsive longitudinal relaxation tuning as a versatile MRI sensing protocol for malignancy targets. Adv Sci. 2018;5(9):1800021.

    Google Scholar 

  • Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: Mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.

    Google Scholar 

Continue Reading

  • Low-Cost, High-Impact Teaching in Pharmacology: A Mixed-Methods Study Assessing the Effectiveness of a Ball-and-Balloon Activity on Student Engagement and Learning Outcomes

    Low-Cost, High-Impact Teaching in Pharmacology: A Mixed-Methods Study Assessing the Effectiveness of a Ball-and-Balloon Activity on Student Engagement and Learning Outcomes

    Continue Reading

  • Audit of Shoulder Dystocia Management and Outcomes at a Busy Hospital in the United Kingdom: A Comprehensive Analysis of Contemporary Practice

    Audit of Shoulder Dystocia Management and Outcomes at a Busy Hospital in the United Kingdom: A Comprehensive Analysis of Contemporary Practice

    Continue Reading

  • How to invest £500 in 2025 like billionaire Warren Buffett

    How to invest £500 in 2025 like billionaire Warren Buffett

    Image source: The Motley Fool

    Anyone new to investing can learn a lot from the sound advice of Warren Buffett. The 95-year-old billionaire is considered the world’s greatest investor, transforming his firm, Berkshire Hathaway, into a $1.1trn super-giant, despite only starting with just $105,100 in 1956.

    Having a hundred grand to kick-start an investing journey is undoubtedly advantageous. Yet, Buffett’s strategy and tactics are still applicable for even the tiniest of investors starting with just £500 today.

    So how can new investors take this small lump sum and transform it into something far more substantial?

    There are two key lessons from Buffett that every novice investor needs to know, in my opinion:

    1. “Rule #1 is never lose money. Rule #2 is never forget Rule # 1”.

    2. “Evaluate companies within your circle of competence”.

    Not every investment Buffett has made has been a success. In fact, there have been some painful mistakes over the years. But by being informed, having some healthy scepticism, and avoiding speculative or reckless investments, the risk of making painful errors can be drastically reduced. That’s how Buffett applies his ‘Rule #1’.

    The second bit of advice is equally as important. Investors don’t need to buy shares in complex bleeding-edge sectors like biotech or exploration-stage mining to make money. Instead, Buffett’s always stuck to the industries that are easy to understand. And some of his most successful investments, like Coca-Cola, have come from these simple sectors.

    In other words, by investing exclusively in industries and companies that are easy to understand, investors can drastically reduce risk from ignorance.

    With all that said, what are some shares that new investors can consider for potentially solid long-term returns?

    There are never any guarantees with any investment since even the most promising of enterprises have to navigate unique risks and challenges. Having said that, one UK Buffett-style stock that I’ve got my eye on right now is Premier Foods (LSE:PFD).

    Premier’s business model is as straightforward as they come. It buys raw ingredients, manufactures food products, and then leverages its branding power to sell them at a premium. And today, 89% of British households buy at least one of its products each year, with an estimated 70% repeat customers.

    In other words, the firm’s brands often find themselves on families’ weekly shopping lists. And with international expansion efforts underway in Australia, Europe, and North America, management‘s seeking to replicate its UK success abroad.

    Is this a high-growth enterprise? No. Is it a highly cash-generative business leveraging its competitive advantages to steadily compound its bottom line? Yes. And with management shoring up the balance sheet over the last five years, the stock’s already more than doubled the performance of the FTSE 100 since 2020.

    Premier Foods still has to deal with the threat of inflationary input costs. While having strong brands certainly helps in passing these costs to customers, weak economic conditions still present a challenge, resulting in both growth and margin pressure.

    Nevertheless, with a proven competitive moat, a discounted valuation, and a long-lasting business model, Premier strikes me as a classic Buffett-style stock to consider. And it’s not the only one, I’ve got my eye on right now.

    The post How to invest £500 in 2025 like billionaire Warren Buffett appeared first on The Motley Fool UK.

    More reading

    Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Premier Foods Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

    Motley Fool UK 2025

    Continue Reading

  • Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis | Journal of Orthopaedic Surgery and Research

    Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis | Journal of Orthopaedic Surgery and Research

  • Bedi A, Bishop J, Keener J, et al. Rotator cuff tears. Nat Rev Dis Primers. 2024;10(1):8.

    Google Scholar 

  • Lewis J. Rotator cuff related shoulder pain: assessment, management and uncertainties. Man Ther. 2016;23:57–68.

    Google Scholar 

  • Lewis J, McCreesh K, Roy JS, Ginn K. Rotator cuff tendinopathy: navigating the diagnosis-management conundrum. J Orthop Sports Phys Ther. 2015;45(11):923–37.

    Google Scholar 

  • Vandvik PO, Lähdeoja T, Ardern C, et al. Subacromial decompression surgery for adults with shoulder pain: a clinical practice guideline. BMJ. 2019;364:l294.

    Google Scholar 

  • Lafrance S, Ouellet P, Alaoui R, et al. Motor control exercises compared to strengthening exercises for upper- and lower-extremity musculoskeletal disorders: a systematic review with meta-analyses of randomized controlled trials. Phys Ther. 2021;101(7):11.

    Google Scholar 

  • Littlewood C, Ashton J, Chance-Larsen K, May S, Sturrock B. Exercise for rotator cuff tendinopathy: a systematic review. Physiotherapy. 2012;98(2):101–9.

    Google Scholar 

  • Lafrance S, Charron M, Dubé OM, et al. The efficacy of exercise therapy for rotator cuff-related shoulder pain according to the FITT principle: a systematic review with meta-analyses. J Orthop Sports Phys Ther. 2024;54(8):499–512.

    Google Scholar 

  • Scott A, Squier K, Alfredson H, et al. ICON 2019: international scientific tendinopathy symposium consensus: clinical terminology. Br J Sports Med. 2020;54(5):260–2.

    Google Scholar 

  • McQuade KJ, Borstad J, de Oliveira AS. Critical and theoretical perspective on scapular stabilization: what does it really mean, and are we on the right track? Phys Ther. 2016;96(8):1162–9.

    Google Scholar 

  • Rees JD, Wolman RL, Wilson A. Eccentric exercises; why do they work, what are the problems and how can we improve them? Br J Sports Med. 2009;43(4):242–6.

    Google Scholar 

  • Malliaras P, Johnston R, Street G, et al. The efficacy of higher versus lower dose exercise in rotator cuff tendinopathy: a systematic review of randomized controlled trials. Arch Phys Med Rehabil. 2020;101(10):1822–34.

    Google Scholar 

  • Baskurt Z, Baskurt F, Gelecek N, Ozkan MH. The effectiveness of scapular stabilization exercise in the patients with subacromial impingement syndrome. J Back Musculoskelet Rehabil. 2011;24(3):173–9.

    Google Scholar 

  • Berg OK, Paulsberg F, Brabant C, et al. High-intensity shoulder abduction exercise in subacromial pain syndrome. Med Sci Sports Exerc. 2021;53(1):1–9.

    Google Scholar 

  • Blume C, Wang-Price S, Trudelle-Jackson E, Ortiz A. Comparison of eccentric and concentric exercise interventions in adults with subacromial impingement syndrome. Int J Sports Phys Ther. 2015;10(4):441–55.

    Google Scholar 

  • Boudreau N, Gaudreault N, Roy JS, Bédard S, Balg F. The addition of glenohumeral adductor coactivation to a rotator cuff exercise program for rotator cuff tendinopathy: a single-blind randomized controlled trial. J Orthop Sports Phys Ther. 2019;49(3):126–35.

    Google Scholar 

  • Clausen MB, Hölmich P, Rathleff M, et al. Effectiveness of adding a large dose of shoulder strengthening to current nonoperative care for subacromial impingement: a pragmatic, double-blind randomized controlled trial (SExSI trial). Am J Sports Med. 2021;49(11):3040–9.

    Google Scholar 

  • Dejaco B, Habets B, van Loon C, van Grinsven S, van Cingel R. Eccentric versus conventional exercise therapy in patients with rotator cuff tendinopathy: a randomized, single blinded, clinical trial. Knee Surg Sports Traumatol Arthrosc. 2017;25(7):2051–9.

    Google Scholar 

  • Dubé MO, Desmeules F, Lewis JS, Roy JS. Does the addition of motor control or strengthening exercises to education result in better outcomes for rotator cuff-related shoulder pain? A multiarm randomised controlled trial. Br J Sports Med. 2023;57(8):457–63.

    Google Scholar 

  • Heron SR, Woby SR, Thompson DP. Comparison of three types of exercise in the treatment of rotator cuff tendinopathy/shoulder impingement syndrome: a randomized controlled trial. Physiotherapy. 2017;103(2):167–73.

    Google Scholar 

  • Hotta GH, De Assis G, Couto A, Cools AM, McQuade KJ, Siriani De Oliveira A. Effects of adding scapular stabilization exercises to a periscapular strengthening exercise program in patients with subacromial pain syndrome: a randomized controlled trial. Musculoskelet Sci Pract. 2020;49:102171.

    Google Scholar 

  • Ingwersen KG, Jensen SL, Sørensen L, et al. Three months of progressive high-load versus traditional low-load strength training among patients with rotator cuff tendinopathy: primary results from the double-blind randomized controlled RoCTEx trial. Orthop J Sports Med. 2017;5(8):2325967117723292.

    Google Scholar 

  • Kamonseki DH, Haik MN, Ribeiro LP, Almeida RF, Camargo PR. Scapular movement training is not superior to standardized exercises in the treatment of individuals with chronic shoulder pain and scapular dyskinesis: randomized controlled trial. Disabil Rehabil. 2023;45(18):2925–35.

    Google Scholar 

  • Macías-Hernández SI, García-Morales JR, Hernández-Díaz C, Tapia-Ferrusco I, Velez-Gutiérrez OB, Nava-Bringas TI. Tolerance and effectiveness of eccentric vs. concentric muscle strengthening in rotator cuff partial tears and moderate to severe shoulder pain. A randomized pilot study. J Clin Orthop Trauma. 2021;14:106–12.

    Google Scholar 

  • Maenhout AG, Mahieu NN, De Muynck M, De Wilde LF, Cools AM. Does adding heavy load eccentric training to rehabilitation of patients with unilateral subacromial impingement result in better outcome? A randomized, clinical trial. Knee Surg Sports Traumatol Arthrosc. 2013;21(5):1158–67.

    Google Scholar 

  • Marzetti E, Rabini A, Piccinini G, et al. Neurocognitive therapeutic exercise improves pain and function in patients with shoulder impingement syndrome: a single-blind randomized controlled clinical trial. Eur J Phys Rehabil Med. 2014;50(3):255–64.

    Google Scholar 

  • Struyf F, Nijs J, Mollekens S, et al. Scapular-focused treatment in patients with shoulder impingement syndrome: a randomized clinical trial. Clin Rheumatol. 2013;32(1):73–85.

    Google Scholar 

  • Chaconas EJ, Kolber MJ, Hanney WJ, Daugherty ML, Wilson SH, Sheets C. Shoulder external rotator eccentric training versus general shoulder exercise for subacromial pain syndrome: a randomized controlled trial. Int J Sports Phys Ther. 2017;12(7):1121–33.

    Google Scholar 

  • Shire AR, Stæhr TAB, Overby JB, Bastholm Dahl M, Sandell Jacobsen J, Høyrup Christiansen D. Specific or general exercise strategy for subacromial impingement syndrome-does it matter? A systematic literature review and meta analysis. BMC Musculoskelet Disord. 2017;18(1):158.

    Google Scholar 

  • Larsson R, Bernhardsson S, Nordeman L. Effects of eccentric exercise in patients with subacromial impingement syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2019;20(1):446.

    Google Scholar 

  • Powell JK, Lewis J, Schram B, Hing W. Is exercise therapy the right treatment for rotator cuff-related shoulder pain? Uncertainties, theory, and practice. Musculoskelet Care. 2024;22(2):e1879.

    Google Scholar 

  • Powell JK, Schram B, Lewis J, Hing W. You have (rotator cuff related) shoulder pain, and to treat it, l recommend exercise. A scoping review of the possible mechanisms underpinning exercise therapy. Musculoskelet Sci Pract. 2022;62:102646.

    Google Scholar 

  • Vila-Dieguez O, Heindel MD, Awokuse D, Kulig K, Michener LA. Exercise for rotator cuff tendinopathy: proposed mechanisms of recovery. Shoulder Elbow. 2023;15(3):233–49.

    Google Scholar 

  • Migliorini F, Maffulli N, Eschweiler J, Schenker H, Tingart M, Betsch M. Arthroscopic versus mini-open rotator cuff repair: a meta-analysis. Surgeon. 2023;21(1):E1–12.

    Google Scholar 

  • Maffulli N, Helander KN, Migliorini F. Tendon appearance at imaging may be altered, but it may not indicate pathology. Knee Surg Sports Traumatol Arthrosc. 2023;31(5):1625–8.

    Google Scholar 

  • Osti L, Del Buono A, Maffulli N. Rotator cuff repair: imaging success and clinical results may not correspond. Orthopedics. 2014;37(1):17–8.

    Google Scholar 

  • Continue Reading